Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial

Michael L. Fisher, Stephen S. Gottlieb, Gary D. Plotnick, Nancy L. Greenberg, Richard D. Patten, Susan K. Bennett, Bruce P. Hamilton

Research output: Contribution to journalArticle

Abstract

Objectives. This clinical trial was performed to determine the safety and clinical impact of titrated metoprolol therapy in patients with heart failure, documented coronary artery disease and a low ejection fraction. Background. Despite known cardiodepressant effects, long-term use of beta-adrenergic antagonists appears to be beneficial in patients with idiopathic dilated cardiomyopathy. However, this therapy has not been critically evaluated in patients with heart failure and coronary artery disease. Methods. In 50 patients with heart failure, known coronary artery disease and an ejection fraction ≤0.40, we examined the impact of metoprolol therapy in a 6-month double-blind, placebo-controlled randomized trial, assessing the frequency of heart failure exacerbations and changes in symptoms (New York Heart Association functional class), ejection fraction and exercise duration. Placebo-treated patients who completed 6-month follow-up studies then underwent a trial with metoprolol therapy (crossover group). Results. Metoprolol was titrated to a mean maximal dose of 87 mg/day (range 25 to 100) without serious adverse reactions. During double-blind therapy, use of a beta-blocker was associated with a significant reduction in the number of hospital admissions (4% vs. 32%, p <0.05), overall improved functional class (p = 0.02), increased ejection fraction (4 ± 7% [mean ± SD] compared with 0 ± 6%, p <0.05) and a greater increase in exercise duration (193 ± 276 vs. 38 ± 213 s with placebo, p <0.01). Crossover outcome paralleled the favorable impact seen during randomized metoprolol therapy. Conclusions. Cautious use of titrated metoprolol appears to be safe and beneficial when added to standard heart failure therapy in patients with dilated cardiomyopathy associated with coronary artery disease.

Original languageEnglish (US)
Pages (from-to)943-950
Number of pages8
JournalJournal of the American College of Cardiology
Volume23
Issue number4
DOIs
StatePublished - Mar 15 1994
Externally publishedYes

Fingerprint

Metoprolol
Coronary Artery Disease
Heart Failure
Placebos
Dilated Cardiomyopathy
Therapeutics
Exercise
Adrenergic beta-Antagonists
Group Psychotherapy
Randomized Controlled Trials
Clinical Trials
Safety

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Fisher, M. L., Gottlieb, S. S., Plotnick, G. D., Greenberg, N. L., Patten, R. D., Bennett, S. K., & Hamilton, B. P. (1994). Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial. Journal of the American College of Cardiology, 23(4), 943-950. https://doi.org/10.1016/0735-1097(94)90641-6

Beneficial effects of metoprolol in heart failure associated with coronary artery disease : A randomized trial. / Fisher, Michael L.; Gottlieb, Stephen S.; Plotnick, Gary D.; Greenberg, Nancy L.; Patten, Richard D.; Bennett, Susan K.; Hamilton, Bruce P.

In: Journal of the American College of Cardiology, Vol. 23, No. 4, 15.03.1994, p. 943-950.

Research output: Contribution to journalArticle

Fisher, ML, Gottlieb, SS, Plotnick, GD, Greenberg, NL, Patten, RD, Bennett, SK & Hamilton, BP 1994, 'Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial', Journal of the American College of Cardiology, vol. 23, no. 4, pp. 943-950. https://doi.org/10.1016/0735-1097(94)90641-6
Fisher, Michael L. ; Gottlieb, Stephen S. ; Plotnick, Gary D. ; Greenberg, Nancy L. ; Patten, Richard D. ; Bennett, Susan K. ; Hamilton, Bruce P. / Beneficial effects of metoprolol in heart failure associated with coronary artery disease : A randomized trial. In: Journal of the American College of Cardiology. 1994 ; Vol. 23, No. 4. pp. 943-950.
@article{5b85ff30d16e4bf4abd664101dbf3c6e,
title = "Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial",
abstract = "Objectives. This clinical trial was performed to determine the safety and clinical impact of titrated metoprolol therapy in patients with heart failure, documented coronary artery disease and a low ejection fraction. Background. Despite known cardiodepressant effects, long-term use of beta-adrenergic antagonists appears to be beneficial in patients with idiopathic dilated cardiomyopathy. However, this therapy has not been critically evaluated in patients with heart failure and coronary artery disease. Methods. In 50 patients with heart failure, known coronary artery disease and an ejection fraction ≤0.40, we examined the impact of metoprolol therapy in a 6-month double-blind, placebo-controlled randomized trial, assessing the frequency of heart failure exacerbations and changes in symptoms (New York Heart Association functional class), ejection fraction and exercise duration. Placebo-treated patients who completed 6-month follow-up studies then underwent a trial with metoprolol therapy (crossover group). Results. Metoprolol was titrated to a mean maximal dose of 87 mg/day (range 25 to 100) without serious adverse reactions. During double-blind therapy, use of a beta-blocker was associated with a significant reduction in the number of hospital admissions (4{\%} vs. 32{\%}, p <0.05), overall improved functional class (p = 0.02), increased ejection fraction (4 ± 7{\%} [mean ± SD] compared with 0 ± 6{\%}, p <0.05) and a greater increase in exercise duration (193 ± 276 vs. 38 ± 213 s with placebo, p <0.01). Crossover outcome paralleled the favorable impact seen during randomized metoprolol therapy. Conclusions. Cautious use of titrated metoprolol appears to be safe and beneficial when added to standard heart failure therapy in patients with dilated cardiomyopathy associated with coronary artery disease.",
author = "Fisher, {Michael L.} and Gottlieb, {Stephen S.} and Plotnick, {Gary D.} and Greenberg, {Nancy L.} and Patten, {Richard D.} and Bennett, {Susan K.} and Hamilton, {Bruce P.}",
year = "1994",
month = "3",
day = "15",
doi = "10.1016/0735-1097(94)90641-6",
language = "English (US)",
volume = "23",
pages = "943--950",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Beneficial effects of metoprolol in heart failure associated with coronary artery disease

T2 - A randomized trial

AU - Fisher, Michael L.

AU - Gottlieb, Stephen S.

AU - Plotnick, Gary D.

AU - Greenberg, Nancy L.

AU - Patten, Richard D.

AU - Bennett, Susan K.

AU - Hamilton, Bruce P.

PY - 1994/3/15

Y1 - 1994/3/15

N2 - Objectives. This clinical trial was performed to determine the safety and clinical impact of titrated metoprolol therapy in patients with heart failure, documented coronary artery disease and a low ejection fraction. Background. Despite known cardiodepressant effects, long-term use of beta-adrenergic antagonists appears to be beneficial in patients with idiopathic dilated cardiomyopathy. However, this therapy has not been critically evaluated in patients with heart failure and coronary artery disease. Methods. In 50 patients with heart failure, known coronary artery disease and an ejection fraction ≤0.40, we examined the impact of metoprolol therapy in a 6-month double-blind, placebo-controlled randomized trial, assessing the frequency of heart failure exacerbations and changes in symptoms (New York Heart Association functional class), ejection fraction and exercise duration. Placebo-treated patients who completed 6-month follow-up studies then underwent a trial with metoprolol therapy (crossover group). Results. Metoprolol was titrated to a mean maximal dose of 87 mg/day (range 25 to 100) without serious adverse reactions. During double-blind therapy, use of a beta-blocker was associated with a significant reduction in the number of hospital admissions (4% vs. 32%, p <0.05), overall improved functional class (p = 0.02), increased ejection fraction (4 ± 7% [mean ± SD] compared with 0 ± 6%, p <0.05) and a greater increase in exercise duration (193 ± 276 vs. 38 ± 213 s with placebo, p <0.01). Crossover outcome paralleled the favorable impact seen during randomized metoprolol therapy. Conclusions. Cautious use of titrated metoprolol appears to be safe and beneficial when added to standard heart failure therapy in patients with dilated cardiomyopathy associated with coronary artery disease.

AB - Objectives. This clinical trial was performed to determine the safety and clinical impact of titrated metoprolol therapy in patients with heart failure, documented coronary artery disease and a low ejection fraction. Background. Despite known cardiodepressant effects, long-term use of beta-adrenergic antagonists appears to be beneficial in patients with idiopathic dilated cardiomyopathy. However, this therapy has not been critically evaluated in patients with heart failure and coronary artery disease. Methods. In 50 patients with heart failure, known coronary artery disease and an ejection fraction ≤0.40, we examined the impact of metoprolol therapy in a 6-month double-blind, placebo-controlled randomized trial, assessing the frequency of heart failure exacerbations and changes in symptoms (New York Heart Association functional class), ejection fraction and exercise duration. Placebo-treated patients who completed 6-month follow-up studies then underwent a trial with metoprolol therapy (crossover group). Results. Metoprolol was titrated to a mean maximal dose of 87 mg/day (range 25 to 100) without serious adverse reactions. During double-blind therapy, use of a beta-blocker was associated with a significant reduction in the number of hospital admissions (4% vs. 32%, p <0.05), overall improved functional class (p = 0.02), increased ejection fraction (4 ± 7% [mean ± SD] compared with 0 ± 6%, p <0.05) and a greater increase in exercise duration (193 ± 276 vs. 38 ± 213 s with placebo, p <0.01). Crossover outcome paralleled the favorable impact seen during randomized metoprolol therapy. Conclusions. Cautious use of titrated metoprolol appears to be safe and beneficial when added to standard heart failure therapy in patients with dilated cardiomyopathy associated with coronary artery disease.

UR - http://www.scopus.com/inward/record.url?scp=0028195009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028195009&partnerID=8YFLogxK

U2 - 10.1016/0735-1097(94)90641-6

DO - 10.1016/0735-1097(94)90641-6

M3 - Article

C2 - 8106700

AN - SCOPUS:0028195009

VL - 23

SP - 943

EP - 950

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 4

ER -